Synthetic, implantable polymers for IUdR radiosensitization of experimental human malignant glioma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 14, Issue 3, 1999, Pages 187-202

  Yuan, Xuan ^a   Dillehay, Larry E ^a   Williams, Jerry R ^a   Williams, Jeffery A ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Biodegradable polymer; Human malignant glioma; Iododeoxyuridine; Radiosensitization

Indexed keywords

IDOXURIDINE; POLYMER; PROPANE; SEBACIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CELL LABELING; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMPLANTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; XENOGRAFT;

EID: 0033031548     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1999.14.187     Document Type: Article

References (38)

1. McLaughlin PW, Lawrence TS, Seabury H, et al. Bromodeoxyuridine-mediated radiosensitization in human glioma: the effect of concentration, duration, and fluoropyrimidine modulation. Int J Radiat Oncol Biol Phys 1994;30:601-7.
2. Uhl V, Phillips TL, Ross GY, Bodell WJ, Rasmussen J. Iododeoxyuridine incorporation and radiosensitization in three human tumor cell lines. Int J Radiat Oncol Biol Phys 1992;22:489-94.
3. Levin VA, Prados MR, Wara WM, et al. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 1995;32:75-83.
4. Fornace AJ, Jr., Dobson PP, Kinsella TJ. Enhancement of radiation damage in cellular DNA following unifilar substitution with iododeoxyuridine. Int J Radiat Oncol Biol Phys 1990;18:873-8.
5. Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure. Int J Radiat Oncol Biol Phys 1990;18:1393-8.
6. Goffinet DR, Brown JM. Comparison of intravenous and intra-arterial pyrimidine infusion as a means of radiosensitizing tumors in vivo. Radiology 1977;124:819-22.
7. Russo A, Gianni L, Kinsella TJ, et al. Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors. Cancer Res 1984;44:1702-5.
8. Jackson D, Kinsella T, Rowland J, et al. Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme. Am J Clin Oncol 1987;10:437-43.
9. Kinsella TJ, Russo A, Mitchell JB, et al. A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer. Int J Radiat Oncol Biol Phys 1985;11:1941-6.
10. Kinsella TJ, Collins J, Rowland J, et al. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J Clin Oncol 1988;6:871-9.
11. Greenberg HS, Chandler WF, Ensminger WD, et al. Radiosensitization with carotid intra-arterial bromodeoxyuridine +/-5-fluorouracil biomodulation for malignant gliomas. Neurology 1994;44:1715-20.
12. Hegarty TJ, Thornton AF, Diaz RF, et al. Intra-arterial bromodeoxyuridine radiosensitization of malignant gliomas. Int J Radiat Oncol Biol Phys 1990;19:421-8.
13. Wirtanen GW, Wiley AL, Vermund H, Stephenson JA, Ansfield FJ. Intraarterial iododeoxyuridine infusion combined with irradiation. A pilot study. Am J Clin Oncol 1990;13:320-3.
14. Cook JA, Glass J, Lebovics R, et al. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine. Cancer Res 1992;52:719-25.
15. Goffman TE, Dachowski LJ, Bobo H, et al. Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation. J Clin Oncol 1992;10:264-8.
16. Urtasun RC, Cosmatos D, DelRowe J, et al. Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: a comparison of short versus long intravenous dose schedules (RTOG 86-12). Int J Radiat Oncol Biol Phys 1993;27:207-14.
17. Bagshaw MA, Doggett RL, Smith KC, Kaplan HS, Nelsen TS. Intra-arterial 5-bromodeoxyuridine and x-ray therapy. Am J Roentgenol Radium Ther Nucl Med 1967;99:886-94.
18. Phuphanich S, Levin EM, Levin VA. Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors. Int J Radiat Oncol Biol Phys 1984;10:1769-72.
19. Pollay M, Roberts PA. Blood-brain barrier: a definition of normal and altered function. Neurosurgery 1980;6:675-85.
20. Brem H. Polymers to treat brain tumours. Biomaterials 1990;11:699-701.
21. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group [see comments]. Lancet 1995;345:1008-12.
22. Walter KA, Cahan MA, Gur A, et al. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 1994;54:2207-12.
23. Gratzner HG. Monoclonal antibody to 5-bromo-and 5-iododeoxyuridine: A new reagent for detection of DNA replication. Science 1982;218:474-5.
24. Vanderlaan M, Thomas CB. Characterization of monoclonal antibodies to bromodeoxyuridine. Cytometry 1985;6:501-5.
25. Williams JA, Dillehay LE, Tabassi K, Sipos E, Fahlman C, Brem H. Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma. J Neurooncol 1997;32:181-92.
26. Ritter MA, Fowler JF, Kim Y, Lindstrom MJ, Kinsella TJ. Single biopsy, tumor kinetic analyses: a comparison of methods and an extension to shorter sampling intervals. Int J Radiat Oncol Biol Phys 1992;23:811-20.
27. Schutte B, Reynders MM, van Assche CL, Hupperets PS, Bosman FT, Blijham GH. An improved method for the immunocytochemical detection of bromodeoxyuridine labeled nuclei using flow cytometry. Cytometry 1987;8:372-6.
28. White RA, Terry NH. A quantitative method for evaluating bivariate flow cytometric data obtained using monoclonal antibodies to bromodeoxyuridine. Cytometry 1992;13:490-5.
29. Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 1992;23:457-67.
30. Hall EJ. Radiobiology for the radiologist. Philadelphia: J.B. Lippincott, 1994.
31. Begg AC, McNally NJ, Shrieve DC, Karcher H. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 1985;6:620-6.
32. Norušis MJ. SPSS for Windows, Advanced Statistics, release 6.0. Chicago, Ill.: Spss, 1993.
33. Perez LA, Dombkowski D, Efird J, Preffer F, Suit HD. Cell proliferation kinetics in human tumor xenografts measured with iododeoxyuridine labeling and flow cytometry: a study of heterogeneity and a comparison between different methods of calculation and other proliferation measurements. Cancer Res 1995;55:392-8.
34. Leong KW, Brott BC, Langer R. Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. J Biomed Mater Res 1985;19:941-55.
35. Budavari S. The Merck index : an encyclopedia of chemicals, drugs, and biologicals. Whitehouse Station, NJ: Merck, 1996.
36. Rodriguez R, Ritter MA, Fowler JF, Kinsella TJ. Kinetics of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo. Int J Radiat Oncol Biol Phys 1994;29:105-13.
37. Ghosh MK, Mitra AK. Enhanced delivery of 5-iodo-2′-deoxyuridine to the brain parenchyma. Pharm Res 1992;9:1173-6.
38. Ghosh MK, Mitra AK. Brain parenchymal metabolism of 5-iodo-2′-deoxyuridine and 5′-ester prodrugs. Pharm Res 1992-9:1048-52.